• linkedin
  • Increase Font
  • Sharebar

    FDA expands ipilimumab approval to pediatric melanoma

    The US Food and Drug Administration (FDA) has expanded the approval of ipilimumab (Yervoy) to include the treatment of pediatric melanoma patients 12 years and older with unresectable or metastatic disease, CancerNetwork reports. The FDA-approved ipilimumab dose for pediatric melanoma patients is 3 mg/kg, administered intravenously every 3 weeks for four doses.

    Read the full report and study details.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow